Seize China Opportunity Quickly, Morgan Stanley Analysts Urge
This article was originally published in The Gray Sheet
Executive Summary
“Barriers to entry are higher than some investors appreciate, and fast followers may be on a path to permanent impairment,” industry analysts note in a recent market research report on the China opportunity for device manufacturers.
You may also be interested in...
Boston Scientific Deepens China Endoscopy Roots
A strategic alliance with Suzhou, China, surgical device firm Frankenman Medical Equipment Company could give Boston Scientific an advantage in the local endoscopy market. Boston points out that more than a million bile duct stone removals are performed with open surgery in China when they could be done with less invasive endoscopy.
‘Made In China’ Provision Removed From Green Channel Policy
The original draft of an accelerated approval policy in China for innovative devices included a condition that a product being considered for the special pathway “is produced in China.” That condition has been removed from the latest draft following pressure from the U.S. government.
‘Made In China’ Provision Removed From Green Channel Policy
The original draft of an accelerated approval policy in China for innovative devices included a condition that a product being considered for the special pathway “is produced in China.” That condition has been removed from the latest draft following pressure from the U.S. government.